Postmarket policy considerations for biosimilar oncology drugs
Matthew J Renwick(London School of Economics and Political Science), Steven G. Morgan(University of British Columbia), Kate Smolina(University of British Columbia), Deirdre Weymann(University of British Columbia), Emilie J. Gladstone(BC Cancer Agency)
Cited by 64
Related Papers
Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps
|The Journal of Antibiotics|2017|240
A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics
|The Journal of Antibiotics|2015|225
Consequences of Moral Distress in the Intensive Care Unit: A Qualitative Study
|American Journal of Critical Care|2017|181
Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults
|Age and Ageing|2016|97
Both New and Chronic Potentially Inappropriate Medications Continued at Hospital Discharge Are Associated With Increased Risk of Adverse Events
|Journal of the American Geriatrics Society|2020|78